Novo Nordisk to showcase new data across its hemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NovoNordiskhemophilia

More Like This

PR Newswire associated0

Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM

PR Newswire associated0

Novo Nordisk submits Biologics License Application (BLA) to FDA for Mim8; an investigational, prophylaxis treatment for people living with hemophilia A with or without inhibitors

PR Newswire associated0

Octapharma's continuing dedication to improving the lives of people with rare bleeding disorders to be showcased at ISTH 2024

PR Newswire associated0

Octapharma to present clinical and scientific data that advances our understanding and treatment of bleeding disorders at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which takes place in Frankfurt, Germany, from February 6 - 9, 2024

Sobi to present new data at ASH 2023 Annual Meeting

PR Newswire associated0

Octapharma to present new clinical and scientific data at ASH 2023 from ongoing research initiatives aimed at advancing care for people living with bleeding disorders

Sobi to present new data at EAHAD 2024

Sobi will showcase extensive research and clinical outcomes at ISTH 2025